Compare KNRX & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KNRX | PYPD |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | Singapore | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.9M | 57.8M |
| IPO Year | 2025 | 2020 |
| Metric | KNRX | PYPD |
|---|---|---|
| Price | $1.98 | $3.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 29.5K | ★ 82.8K |
| Earning Date | 06-12-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,820,365.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.00 | N/A |
| 52 Week Low | $1.25 | $2.30 |
| 52 Week High | $4.00 | $4.05 |
| Indicator | KNRX | PYPD |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 64.05 |
| Support Level | N/A | $3.72 |
| Resistance Level | N/A | $3.98 |
| Average True Range (ATR) | 0.00 | 0.15 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 86.00 |
Knorex Ltd is a B2B technology company providing programmatic advertising products and solutions to marketers to streamline and automate their advertising and marketing workflows. Its software offers marketers cost-effective solutions and productivity-enhancing capabilities to target audience across various advertising channels and devices through automated processes and algorithms, which is known as programmatic advertising. Its product, Knorex XPOSM, is a self-service enterprise-grade cloud platform with a suite of advertising management and execution (AMX) applications. The Company operates in one operating segment, which focuses on platform subscription fee, platform services, managed activations, and professional services.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.